| Literature DB >> 33362547 |
Jingwei Yao1,2, Kun Deng3, Jialu Huang3, Ruimin Zeng1, Jianhong Zuo1,3,2.
Abstract
Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mechanism of tamoxifen resistance. In recent years, with progress in research into the protective autophagy of drug-resistant cells and cell cycle regulators, major breakthroughs have been made in research on tamoxifen resistance. For a better understanding of the mechanism of tamoxifen resistance, protective autophagy, cell cycle regulators, and some transcription factors and enzymes regulating the expression of the estrogen receptor are summarized in this review. In addition, recent progress in reducing resistance to tamoxifen is reviewed. Finally, we discuss the possible research directions into tamoxifen resistance in the future to provide assistance for the clinical treatment of breast cancer.Entities:
Keywords: autophagy; breast cancer; cell cycle regulators; resistance; tamoxifen
Year: 2020 PMID: 33362547 PMCID: PMC7758911 DOI: 10.3389/fphar.2020.592912
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810